Skip to Main Content

Paper Details

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer.
Clin Cancer Res
60
2017
AKT, Anastrozole, C1D17, C1D17 biopsies, ER, ER+, ESR1, ESR1 mutation, HER2, MK-2206, PIK3CA, PIK3CA mutant, PIK3CA-Mutant, PIK3CA-mutant ER+, PIK3CA-mutant ER+ breast cancer, PIK3CA-mutant tumors, PRAS40, Patients, Rash, anastrozole, breast cancer, estrogen, estrogen receptor, estrogen receptor-positive (ER+) breast cancer, goserelin, pan-, patient, patients, tumor
Author NameAffiliation
Cynthia X MaWashington University School of Medicine
Cynthia X MaWashington University School of Medicine
Vera J SumanMayo Clinic
Matthew P GoetzMayo Clinic
Foluso O AdemuyiwaWashington University School of Medicine
Foluso O AdemuyiwaWashington University School of Medicine
Charles L LoprinziMayo Clinic
Erica K BarnellWashington University School of Medicine
Erica K BarnellMcDonnell Genome Institute, Washington University School of Medicine
Zachary L SkidmoreMcDonnell Genome Institute, Washington University School of Medicine
Yang-Yang FengWashington University School of Medicine
Yang-Yang FengMcDonnell Genome Institute, Washington University School of Medicine
Kilannin KrysiakWashington University School of Medicine
Kilannin KrysiakMcDonnell Genome Institute, Washington University School of Medicine
Jeremy HoogWashington University School of Medicine
Jeremy HoogWashington University School of Medicine
Zhanfang GuoWashington University School of Medicine
Zhanfang GuoWashington University School of Medicine
Elaine R MardisWashington University School of Medicine
Elaine R MardisWashington University School of Medicine
Elaine R MardisMcDonnell Genome Institute, Washington University School of Medicine
Elaine R MardisWashington University School of Medicine
Elaine R MardisMcDonnell Genome Institute, Washington University School of Medicine
Elaine R MardisWashington University School of Medicine
Ian S HagemannWashington University School of Medicine
Souzan SanatiWashington University School of Medicine
Obi L GriffithWashington University School of Medicine
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine
Obi L GriffithWashington University School of Medicine
Malachi GriffithWashington University School of Medicine
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine
Malachi GriffithWashington University School of Medicine
Matthew J EllisBaylor College of Medicine
  • 1 - 33

Datasets

Release 1.2